These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12879889)

  • 41. Initiating warfarin therapy: 5 mg versus 10 mg.
    Eckhoff CD; Didomenico RJ; Shapiro NL
    Ann Pharmacother; 2004 Dec; 38(12):2115-21. PubMed ID: 15522981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.
    Cunningham RS
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy.
    Goldhaber SZ
    J Thromb Thrombolysis; 2006 Feb; 21(1):51-2. PubMed ID: 16475042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 47. Mars or venus--is sex a risk factor for recurrent venous thromboembolism?
    Elliott CG; Rubin LJ
    N Engl J Med; 2004 Jun; 350(25):2614-6. PubMed ID: 15201419
    [No Abstract]   [Full Text] [Related]  

  • 48. Thrombosis prophylaxis in cancer patients with a central venous catheter.
    Laporte S; Decousus H; Mismetti P
    Arch Intern Med; 2004 Feb; 164(4):459; author reply 459-60. PubMed ID: 14980999
    [No Abstract]   [Full Text] [Related]  

  • 49. Long term anticoagulation of idiopathic venous thromboembolism: do we have the answers?
    Goldhaber S
    Clin Adv Hematol Oncol; 2003 May; 1(5):276-7. PubMed ID: 16224420
    [No Abstract]   [Full Text] [Related]  

  • 50. Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol.
    Beksaç B; González Della Valle A; Anderson J; Sharrock NE; Sculco TP; Salvato EA
    Clin Orthop Relat Res; 2007 Oct; 463():114-9. PubMed ID: 17960674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
    Tran H; McRae S; Ginsberg J
    Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism.
    Monkman K; Lazo-Langner A; Kovacs MJ
    Thromb Res; 2009 Jul; 124(3):275-80. PubMed ID: 19155056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 55. A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
    Frezza EE; Wachtel MS
    Obesity (Silver Spring); 2006 Nov; 14(11):1961-5. PubMed ID: 17135612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current issues in the initial phase of warfarin therapy].
    Squizzato A; Steidl L; Ageno W
    Recenti Prog Med; 2005 Dec; 96(12):612-5. PubMed ID: 16496748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice.
    Wittkowsky AK
    Am J Manag Care; 2004 Oct; 10(10 Suppl):S297-306; discussion S312-7. PubMed ID: 15605700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of combined modality prophylaxis including short-duration warfarin to prevent venous thromboembolism after total hip arthroplasty.
    Keeney JA; Clohisy JC; Curry MC; Maloney WJ
    J Arthroplasty; 2006 Jun; 21(4):469-75. PubMed ID: 16781396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.